34 Grants (Page 1 of 2)
2021
Discovery and development of Ku-targeted small molecule inhibitors: A novel mechanism of DNA-PK inhibition
GAVANDE, NAVNATH S and Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA247370-02), $584,470USD, 2020-03-13 -- 2025-02-28
 
Novel DNA damage response therapeutics targeting replication protein A
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA257430-01A1), $509,008USD, 2021-07-01 -- 2026-06-30
2020
Discovery and development of Ku-targeted small molecule inhibitors: A novel mechanism of DNA-PK inhibition
GAVANDE, NAVNATH S and Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA247370-01A1), $603,569USD, 2020-03-13 -- 2025-02-28
2017
A new generation of targeted therapeutics for the treatment of cancer.
PAWELCZAK, KATHERINE and Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R41CA195926-01S1), $49,844USD, 06/01/2015 -- 05/31/2017
 
Targeting nucleotide excision repair in combination cancer therapy
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA180710-05), $323,700USD, 09/30/2013 -- 08/31/2018
2016
Chemical enhancement of CRISPR/Cas9 mediated site-specific genome engineering
PAWELCZAK, KATHERINE and Turchi, John J
National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS) (ID: 1R43GM119880-01), $293,005USD, 06/01/2016 -- 05/31/2017
 
Targeting nucleotide excision repair in combination cancer therapy
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 4R01CA180710-04), $323,700USD, 09/30/2013 -- 08/31/2018
2015
Development of novel lung cancer therapeutics targeting the DNA damage response
Turchi, John J and PAWELCZAK, KATHERINE
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R41CA195926-01), $249,431USD, 06/01/2015 -- 05/31/2016
 
Targeting nucleotide excision repair in combination cancer therapy
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA180710-03), $323,700USD, 09/30/2013 -- 08/31/2018
2014
Targeting nucleotide excision repair in combination cancer therapy
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA180710-02), $313,989USD, 09/30/2013 -- 08/31/2018
2013
Development of Novel Agents Targeting Genome Stability and Maintenance for Treati
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R41CA162648-01S1), $131,247USD, 09/01/2013 -- 08/31/2014
 
Targeting nucleotide excision repair in combination cancer therapy
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA180710-01A1), $323,700USD, 09/30/2013 -- 08/31/2018
2012
Development of Novel Agents Targeting Genome Stability and Maintenance for Treati
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R41CA162648-01), $229,680USD, 09/21/2012 -- 08/31/2014
 
Targeting the ERCC1/XPF nuclease for cancer therapy
FELTGEN, ROBERT and Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R43CA165848-01A1), $299,922USD, 09/26/2012 -- 08/31/2014
2011
Recognition and Repair of Cisplatin-DNA Damage
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA082741-10), $206,327USD, 07/01/2000 -- 07/31/2013
2010
Recognition and Repair of Cisplatin-DNA Damage
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA082741-09), $212,708USD, 07/01/2000 -- 07/31/2012
2009
Development of methodologies for the analysis of DNA repair capacity to predict t
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA128628-02), $204,156USD, 09/15/2008 -- 08/31/2010
 
Recognition and Repair of Cisplatin-DNA Damage
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA082741-08), $212,708USD, 07/01/2000 -- 07/31/2012
2008
Development of methodologies for the analysis of DNA repair capacity to predict t
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R21CA128628-01A1), $170,130USD, 09/15/2008 -- 08/31/2010
 
Recognition and Repair of Cisplatin-DNA Damage
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA082741-07), $212,708USD, 07/01/2000 -- 07/31/2012
2007
Recognition and Repair of Cisplatin-DNA Damage
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 2R01CA082741-06A2), $212,708USD, 07/01/2000 -- 07/31/2012
2004
RECOGNITION AND REPAIR OF CISPLATIN DNA DAMAGE
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA082741-05), $193,050USD, 07/01/2000 -- 06/30/2006
2003
RECOGNITION AND REPAIR OF CISPLATIN DNA DAMAGE
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA082741-04), $193,050USD, 07/01/2000 -- 06/30/2005
2002
RECOGNITION AND REPAIR OF CISPLATIN DNA DAMAGE
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA082741-03), $264,550USD, 07/01/2000 -- 06/30/2005
2001
RECOGNITION AND REPAIR OF CISPLATIN DNA DAMAGE
Turchi, John J
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA082741-02), $264,550USD, 07/01/2000 -- 06/30/2005